252 related articles for article (PubMed ID: 30305524)
1. [Treatment strategy for relapsed or refractory myeloma according to the new Guidelines].
Ozaki S
Rinsho Ketsueki; 2018; 59(10):2178-2188. PubMed ID: 30305524
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
[TBL] [Abstract][Full Text] [Related]
3. [Management of multiple myeloma in the relapsed/refractory patient].
Tabayashi T
Rinsho Ketsueki; 2019; 60(9):1257-1264. PubMed ID: 31597851
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Relapsed/Refractory Multiple Myeloma.
Neri P; Bahlis NJ; Paba-Prada C; Richardson P
Cancer Treat Res; 2016; 169():169-194. PubMed ID: 27696263
[TBL] [Abstract][Full Text] [Related]
5. Current strategies for treatment of relapsed/refractory multiple myeloma.
Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
[TBL] [Abstract][Full Text] [Related]
7. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
8. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
Nijhof IS; van de Donk NWCJ; Zweegman S; Lokhorst HM
Drugs; 2018 Jan; 78(1):19-37. PubMed ID: 29188449
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ashjian E; Redic K
J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
[TBL] [Abstract][Full Text] [Related]
10. [Current treatment of refractory and relapsed multiple myeloma].
Sasaki M
Rinsho Ketsueki; 2016; 57(10):2084-2095. PubMed ID: 27795518
[TBL] [Abstract][Full Text] [Related]
11. [Multiple myeloma : What has been confirmed in therapy?].
Baertsch MA; Goldschmidt H
Internist (Berl); 2017 Dec; 58(12):1250-1257. PubMed ID: 29098319
[TBL] [Abstract][Full Text] [Related]
12. [Treatment algorithms for multiple myeloma in Japan].
Ozaki S
Rinsho Ketsueki; 2017; 58(8):1014-1023. PubMed ID: 28883264
[TBL] [Abstract][Full Text] [Related]
13. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Dimopoulos MA; Richardson P; Lonial S
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):460-473. PubMed ID: 35148975
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
Moreau P; de Wit E
Br J Haematol; 2017 Oct; 179(2):198-218. PubMed ID: 28556890
[TBL] [Abstract][Full Text] [Related]
15. New pharmacotherapy options for multiple myeloma.
Mina R; Cerrato C; Bernardini A; Aghemo E; Palumbo A
Expert Opin Pharmacother; 2016; 17(2):181-92. PubMed ID: 26684262
[TBL] [Abstract][Full Text] [Related]
16. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
Moreau P
Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
[TBL] [Abstract][Full Text] [Related]
17. The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma.
Hajek R; Siegel D; Orlowski RZ; Ludwig H; Palumbo A; Dimopoulos M
Leuk Lymphoma; 2014 Jan; 55(1):11-8. PubMed ID: 23614765
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma: from front-line to relapsed therapies.
Moreau P; Touzeau C
Am Soc Clin Oncol Educ Book; 2015; ():e504-11. PubMed ID: 25993216
[TBL] [Abstract][Full Text] [Related]
19. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
Ri M
Rinsho Ketsueki; 2018; 59(10):2162-2168. PubMed ID: 30305522
[TBL] [Abstract][Full Text] [Related]
20. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
van de Donk NW; Lokhorst HM
Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
